Heart Failure

Phase 1/2 data prompted the RMAT designation for HLHS shortly after Mesoblast announced positive phase 3 data for HFrEF.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

A nasal spray form of bumetanide reduced tissue swelling from heart failure as effectively as the oral and intravenous formulations.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

Initial catheter ablation achieved a lower risk of a composite primary endpoint event than anti-arrhythmic drug therapy in patients who survived a heart attack.

Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

Optimal use of GDMT therapy in heart failure could save an estimated 1.19 million lives globally over the course of 1 year.

Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

Deepak Bhatt, MD, MPH, MBA, discusses the results of a prespecified analysis of the EMPACT-MI trial examining the effect across the spectrum of baseline kidney function.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.